Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 8Unknown 7Terminated 4Withdrawn 3Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Fractures, Bone 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Toremifene × Clear all
NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT00003865 2017-07-13

Toremifene in Treating Patients With Ovarian Cancer

George Washington University

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01214291 2013-11-15

TREAT2

GTx

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms, Fractures, Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡